These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2134116)

  • 1. Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy.
    Aldenkamp AP; van Wieringen A; Alpherts WC; van Emde Boas W; Haverkort HA; de Vries J; Meinardi H
    Neuropsychobiology; 1990-1991; 24(2):90-101. PubMed ID: 2134116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?
    Gainotti G; Nocentini U; Sena E
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13 Suppl():S47-59. PubMed ID: 2694229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree.
    Villardita C; Grioli S; Lomeo C; Cattaneo C; Parini J
    Neuropsychobiology; 1992; 25(1):24-8. PubMed ID: 1603291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life.
    Saletu B; Linzmayer L; Grünberger J; Pietschmann H
    Neuropsychobiology; 1985; 13(1-2):44-52. PubMed ID: 3897895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study.
    Moglia A; Sinforiani E; Zandrini C; Gualtieri S; Corsico R; Arrigo A
    Clin Neuropharmacol; 1986; 9 Suppl 3():S73-8. PubMed ID: 3594459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxiracetam in dementia: a double-blind, placebo-controlled study.
    Bottini G; Vallar G; Cappa S; Monza GC; Scarpini E; Baron P; Cheldi A; Scarlato G
    Acta Neurol Scand; 1992 Sep; 86(3):237-41. PubMed ID: 1414239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sabeluzole (R 58,735) on memory functions in patients with epilepsy.
    Aldenkamp AP; Overweg J; Smakman J; Beun AM; Diepman L; Edelbroek P; Gutter T; Mulder OG; vt Slot B; Vledder B
    Neuropsychobiology; 1995; 32(1):37-44. PubMed ID: 7566521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical and neurophysiological trial on nootropic drugs in patients with mental decline.
    Gallai V; Mazzotta G; Del Gatto F; Montesi S; Mazzetti A; Dominici P; Della Monica A
    Acta Neurol (Napoli); 1991 Feb; 13(1):1-12. PubMed ID: 1867125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia.
    Rozzini R; Zanetti O; Bianchetti A
    Acta Neurol (Napoli); 1992 Apr; 14(2):117-26. PubMed ID: 1414555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.
    Rozzini R; Zanetti O; Bianchetti A
    Acta Neurol (Napoli); 1993 Feb; 15(1):44-52. PubMed ID: 8456595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.
    Villardita C; Parini J; Grioli S; Quattropani M; Lomeo C; Scapagnini U
    J Neural Transm Suppl; 1987; 24():293-8. PubMed ID: 3479527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy.
    Hamberger MJ; Palmese CA; Scarmeas N; Weintraub D; Choi H; Hirsch LJ
    Epilepsia; 2007 Jul; 48(7):1283-91. PubMed ID: 17484756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive psychophysiology in nootropic drug research: effects of Ginkgo biloba on event-related potentials (P300) in age-associated memory impairment.
    Semlitsch HV; Anderer P; Saletu B; Binder GA; Decker KA
    Pharmacopsychiatry; 1995 Jul; 28(4):134-42. PubMed ID: 7491367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CNS pharmacology and clinical therapeutic effects of oxiracetam.
    Itil TM; Menon GN; Songar A; Itil KZ
    Clin Neuropharmacol; 1986; 9 Suppl 3():S70-2. PubMed ID: 3594458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long latency auditory evoked potentials in schoolchildren and adolescents with epilepsy].
    Zgorzalewicz M
    Przegl Lek; 2006; 63 Suppl 1():8-13. PubMed ID: 17471817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organic brain syndrome treated with oxiracetam. A double-blind randomized controlled trial.
    Hjorther A; Browne E; Jakobsen K; Viskum P; Gyntelberg F
    Acta Neurol Scand; 1987 Apr; 75(4):271-6. PubMed ID: 3296624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment.
    Semlitsch HV; Anderer P; Saletu B; Hochmayer I
    Neuropsychobiology; 1990-1991; 24(1):49-56. PubMed ID: 2132641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrical sources of P300 event-related brain potentials revealed by low resolution electromagnetic tomography. 2. Effects of nootropic therapy in age-associated memory impairment.
    Anderer P; Saletu B; Semlitsch HV; Pascual-Marqui RD
    Neuropsychobiology; 1998; 37(1):28-35. PubMed ID: 9438269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxiracetam or fastigial nucleus stimulation reduces cognitive injury at high altitude.
    Hu S; Shi J; Xiong W; Li W; Fang L; Feng H
    Brain Behav; 2017 Oct; 7(10):e00762. PubMed ID: 29075554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study.
    Maina G; Fiori L; Torta R; Fagiani MB; Ravizza L; Bonavita E; Ghiazza B; Teruzzi F; Zagnoni PG; Ferrario E
    Neuropsychobiology; 1989; 21(3):141-5. PubMed ID: 2693996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.